Marcus Kostka

Marcus Kostka is a highly experienced biotech industry expert. Prior to joining Abalos as CEO, he held various roles at Boehringer Ingelheim, his latest position being Venture Fund Partner since 2014. In this role, he was board member in EtheRNA NV, Cardior Pharmaceutical, Aelin Therapeutics and Rewind Therapeutics.

During his board membership he participated in the successful exits of Rigontec GmbH and ICD Therapeutics GmbH. Before, he was responsible for external resourcing and innovation in the area of cardiometabolic, CNS and respiratory research as well as for international research collaborations with external partners as Director of External Innovation and Director of Corporate Research Networking, respectively. From 2006 – 2009 as R&D Project Leader, Marcus was leading project teams from preclinical development until clinical phase II studies in the area of oncology, urology, metabolism and CNS diseases.

He joined Boehringer Ingelheim in 1996 as a PhD student in the area of Alzheimer´s disease research and, after a postdoc period, transitioned to the company’s Parkinson disease research group in Biberach as molecular biology Lab Head. Marcus holds a Diploma in Biology with focus on Genetics and Biochemistry from the Johannes Gutenberg University in Mainz, Germany.